ClinicalTrials.gg
RecruitingNCT05900245Updated Jan 26, 2024

Anesthesia Induction Schemes of Electroconvulsive Convulsions in Patients With Depression Based on EEG Monitoring

An interventional study of Index of consciousness+Anesthetic(propofol)+Muscle relaxant(Succinylcholine) in Depression, Electroconvulsive Therapy and Electroencephalography, sponsored by Min Su. Recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-01-26.

Sponsored by Min Su · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2024, 2 years 7 months ago, but the record still lists the study as recruiting.
  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 358 studies in Depression with a site in China — 119 open to participants now, 138 under way, 3 of them phase 3. Depression · China.

Planned enrollment
278th of 284
24 · median 129
Started
2023
with 43 others
No phase
218 of 358
71 open now
Primary completion
2024-03
later than 8 of 137 live
Registered
170th of 358
by date

Among the 358 studies in Depression with a site in China, this one is the 278th largest by planned enrollment of the 284 interventional ones that give a count, is one of 44 that started in 2023, is one of 218 with no phase, reaches primary completion later than 8 of the 137 other live ones, and was the 170th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

119 of the 358 studies in Depression with a site in China are open now. Recruiting first, the newest first:

114 more — sign in →

All 119 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 358 studies in Depression with a site in China, or all of them as a file.
02

Study summary

Depression is a common clinical mental disease with high incidence rate, high recurrence rate, high suicide rate and high disability rate. As a first-line treatment for depression with refractory, high suicide risk and obvious psychotic symptoms, electric shock has a definite effect on depression, but may lead to cognitive impairment. The induction of extensive epileptiform discharges in the cerebral cortex by electric shock therapy is the key to ensure the treatment effect. The level of epileptiform discharges in the brain is mainly reflected in the quality of convulsions. The quality of electroconvulsive convulsions is affected by factors such as age, stimulation power, anesthetic drugs and depth of anesthesia. Most anesthetics have anticonvulsive properties, such as barbiturate or propofol, which may have a negative impact on the quality of convulsions, thus affecting the therapeutic effect. If the parameters of electric shock, such as stimulation dose, are modified, although the quality and treatment effect of convulsions can be improved, it may also lead to higher cognitive side effects. The depth of anesthesia also affects the quality and efficacy of electric shock convulsions, and the quality of convulsions is higher when stimulated at a shallow level of anesthesia. However, if the use of narcotic drugs is reduced to improve the quality of convulsions, the risk of restlessness and delirium after electric shock may be higher and the comfort of patients may be lower. Therefore, this study compared the effects of different anesthesia induction schemes on the quality and clinical efficacy of electroconvulsive seizures in patients with depression based on EEG monitoring, and explored the optimal depth of anesthesia.

Read the detailed description

This study is a randomized controlled, single blind clinical trial comparing the quality of convulsions and clinical effects of electroconvulsive therapy under different levels of consciousness index (IoC).A total of 24 participants were included in this study, all from the inpatient department of the Psychiatric Department of the First Affiliated Hospital of Chongqing Medical University. They were diagnosed as depression patients according to the International Classification of Diseases (ICD-11), and their depression level and cognitive function level were evaluated by trained psychiatrists; In the study, the subjects use the EEG bispectral index monitor (Apollo-9000A) to monitor IoC1(Index of consciousness 1) and IoC2(Index of consciousness 2) before electric shock.Then anesthesia induction was performed using propofol 1.5mg/kg and scoline 1mg/kg. According to the difference in consciousness index 1 (IoC1), the subjects were randomly divided into three groups, namely H group (IoC1 60-70), M group (IoC1 50-60), and L group (IoC1 40-50). All subjects underwent assisted breathing after anesthesia induction, monitoring the concentration of end-expiratory carbon dioxide, and conducting electrical stimulation when the consciousness index reached the corresponding level,and the electrode position is bilateral temporal area. The main outcome measure is EEG seizure duration ,and the secondary outcome measures include average Seizure Energy Index(SEI), electric shock stimulation energy, post-seizure inhibition index, the fastest heart rate, Hamilton Depression Scale (HAMD-24) score, Montreal Cognitive Assessment Scale (MoCA) score, adverse reactions during awakening and the interval between anesthesia induction and the start of electrical stimulation.

Due to the varying frequency of electroconvulsive therapy performed by each subject, with an average of 6-12 times and varying duration of each electroconvulsive treatment, this study uses a mixed effects model to analyze the relationship between different consciousness indices and patient factors on the duration of EEG seizures. The depression score and cognitive function score before and after the complete course of electric shock are compared between groups using LSD-t test.

03

Conditions studied

  • Depression
  • Electroconvulsive Therapy
  • Electroencephalography

Browse trials for

Keywords

  • Depression,Electroconvulsive Therapy,Electroencephalography
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • In-patients who meet the diagnostic criteria of moderate and severe depression in the 11th edition of the International Classification of Diseases (ICD-11)
  • Age 18-60 years old, gender unlimited
  • Primary school or above education level
  • Indications for MECT treatment
  • Normal hearing and vision (including color discrimination)
  • The patient voluntarily participated in the study and signed the form, and the guardian also signed the informed consent form.

Exclusion criteria

Exclusion Criteria:

  • History of physical disease, brain organic disease and abuse of alcohol and psychoactive substances
  • Patients with bipolar disorder
  • Primary insomnia
  • Combined with other mental diseases
  • Combined with obesity, diabetes and other metabolic diseases
  • Combined with hypertension, cardiovascular disease or cerebrovascular disease
  • Combined with Alzheimer's disease
  • Pregnant and lactating women.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Active comparator
    Group H:IoC1 60-70

    This study used an EEG bispectral index monitor (Apolo 9000A) to monitor consciousness index 1 (IoC1) and consciousness index 2 (IoC2) before electric shock, and then induced anesthesia with propofol 1.5mg/kg and succinylcholine 1mg/kg, following by mask pressurized oxygen supply,dental pads protect the tongue and monitoring the concentration of end-expiratory carbon dioxide. Electrical stimulation is performed when the consciousness index 1 is between 60 and 70. The electrode is located on the bilateral temporal side;Electric shock equipment:ThymatronSystem Ⅳ Electroconvulsive System,manufacturer:SOMATICS, USA;Propofol manufacturer: AstraZeneca of the UK, concentration: 10mg/ml. Succinylcholine manufacturer: Shanghai Xudong Haipu Pharmaceutical Co., Ltd.China, concentration: 2ml: 0.1g.

    Other: Index of consciousness+Anesthetic(propofol)+Muscle relaxant(Succinylcholine)

  • Active comparator
    Group M: IoC1 50-60

    This study used an EEG bispectral index monitor (Apolo 9000A) to monitor consciousness index 1 (IoC1) and consciousness index 2 (IoC2) before electric shock, and then induced anesthesia with propofol 1.5mg/kg and succinylcholine 1mg/kg, following by mask pressurized oxygen supply,dental pads protect the tongue and monitoring the concentration of end-expiratory carbon dioxide. Electrical stimulation is performed when the consciousness index 1 is between 50 and 60. The electrode is located on the bilateral temporal side;Electric shock equipment:ThymatronSystem Ⅳ Electroconvulsive System,manufacturer:SOMATICS, USA;Propofol manufacturer: AstraZeneca of the UK, concentration: 10mg/ml. Succinylcholine manufacturer: Shanghai Xudong Haipu Pharmaceutical Co., Ltd.China, concentration: 2ml: 0.1g.

    Other: Index of consciousness+Anesthetic(propofol)+Muscle relaxant(Succinylcholine)

  • Active comparator
    Group L:IoC1 40-50

    This study used an EEG bispectral index monitor (Apolo 9000A) to monitor consciousness index 1 (IoC1) and consciousness index 2 (IoC2) before electric shock, and then induced anesthesia with propofol 1.5mg/kg and succinylcholine 1mg/kg, following by mask pressurized oxygen supply,dental pads protect the tongue and monitoring the concentration of end-expiratory carbon dioxide. Electrical stimulation is performed when the consciousness index 1 is between 40 and 50. The electrode is located on the bilateral temporal side;Electric shock equipment:ThymatronSystem Ⅳ Electroconvulsive System,manufacturer:SOMATICS, USA;Propofol manufacturer: AstraZeneca of the UK, concentration: 10mg/ml. Succinylcholine manufacturer: Shanghai Xudong Haipu Pharmaceutical Co., Ltd.China, concentration: 2ml: 0.1g.

    Other: Index of consciousness+Anesthetic(propofol)+Muscle relaxant(Succinylcholine)

Interventions

  • OtherIndex of consciousness+Anesthetic(propofol)+Muscle relaxant(Succinylcholine)

    EEG monitoring is performed before induction of electrical shock anesthesia(propofol1.5mg/kg+Succinylcholine1mg/kg), and the timing of electrical stimulation is determined based on the level of consciousness index 1 displayed on the EEG.

06

What researchers measure

Primary outcomes

  1. EEG seizure duration

    Duration of EEG convulsions, in seconds,the most important index of the quality of EEG during the treatment of electric shock

    Time frame: up to 30 minutes after each electroconvulsive treatment

Secondary outcomes

  1. average Seizure Energy Index(SEI)

    Indicator of quality of convulsive, in uV2

    Time frame: up to 30 minutes after each electroconvulsive treatment

  2. electric shock stimulation energy

    Indicator of electric shock stimulation energy, in mC

    Time frame: up to 30 minutes after each electroconvulsive treatment

  3. post-seizure inhibition index

    Indicator of quality of convulsive, in %

    Time frame: up to 30 minutes after each electroconvulsive treatment

  4. Bispectral EEG monitoring index

    Depth of sedation and injury stress index,Value range 0-100

    Time frame: up to 30 minutes after each electroconvulsive treatment

  5. Maximun heart rate

    Maximum heart rate during electrical stimulation,in times/minute

    Time frame: up to 30 minutes after each electroconvulsive treatment

  6. Hamilton score

    Depression score,A total score of 81 points, ≤ 8 points without depression, 8-20 points with possible depression, 20-35 points with mild to moderate depression, ≥ 35 points with severe depression

    Time frame: through study completion, an average of 1 year

  7. Montreal cognitive score

    cognitive function assessment,A total score of 30 points,\<26 points determines the presence of cognitive impairment

    Time frame: through study completion, an average of 1 year

  8. Recovery period restlessness

    Complications during anesthesia recovery,Using Richmond restless sedation scale

    Time frame: up to 4 hours after each electroconvulsive treatment

  9. Recovery period delirium

    Complications during anesthesia recovery,Using CAM-ICU scale

    Time frame: up to 4 hours after each electroconvulsive treatment

  10. Recovery period nausea and vomiting

    Complications during anesthesia recovery,Using index of nausea and vomiting and retching(R-INVR)

    Time frame: up to 4 hours after each electroconvulsive treatment

  11. Recovery period muscle soreness, headache, dizziness

    Complications during anesthesia recovery,Using 0 for none, 1 for yes

    Time frame: up to 4 hours after each electroconvulsive treatment

  12. interval between anesthesia induction and the start of electrical stimulation

    Time to wait for electrical stimulation after administration,in seconds

    Time frame: up to 4 hours after each electroconvulsive treatment

  13. intraoperative awareness

    During general anesthesia, consciousness recovery occurs, and the patient has a certain degree of perception and memory of the surrounding environment or sound. After general anesthesia, the patient can recall what happened during the surgery and be informed of any pain or other conditions. Events occurring before induction to sleep and after awakening from anesthesia were not included.

    Time frame: up to 4 hours after each electroconvulsive treatment

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Mar 2024, 9 months after the start.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 9 months is below that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2023
First posted
Jun 12, 2023
StartActual
Jun 12, 2023
Primary completionEst.
Mar 31, 2024
CompletionEst.
Aug 31, 2024
Last update
Jan 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05900245
Lead sponsor
Min Su
Responsible party
Min Su (Professor of Anesthesiology, First Affiliated Hospital of Chongqing Medical University) — Sponsor-investigator
First posted
Jun 12, 2023
Start date
Jun 12, 2023
Primary completion
Mar 31, 2024 (estimated)
Completion
Aug 31, 2024 (estimated)
Last update
Jan 26, 2024

Study contacts

Zhao B shu, MM
Contact
bangshuzhao@163.com
+8615823079815
Min Su, BM
study director · First Affiliated Hospital of Chongqing Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion